Competitive Technologies Announces Results of Pilot Trials Using Calmare(R) Medical Device With "Scrambler Therapy"(TM) Technology

        Print
| Source: Competitive Technologies, Inc.

FAIRFIELD, Conn., May 18, 2012 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) announced today the availability of two clinical trial abstracts announced by the American Society of Clinical Oncology (ASCO). Both abstracts indicate positive effects from the use of the Calmare® medical device with "Scrambler Therapy"™ technology. One study is on patients suffering from chemotherapy-induced peripheral neuropathy (CIPN) and the other is on patients suffering from post-herpetic neuropathy (PHN).

The first abstract from authors at Mayo Clinic and Johns Hopkins University says, "Chemotherapy-induced peripheral neuropathy (CIPN), a common dose-limiting side effect of chemotherapy, remains without known effective interventions. Preliminary data support that Scrambler Therapy, a device which treats pain via non-invasive cutaneous electrostimulation, is beneficial for the treatment of CIPN."

The results presented were from a pilot study of the first 11 CIPN patients, with more patients being entered into the trial. The study reported a reduction in mean pain score of 48% while reduction in worst pain scores was 36%. Tingling scores declined 41% to 43% and numbness declined 21% to 28% on mean-worst pain. (To view the complete abstract, visit http://abstract.asco.org/AbstView_114_94886.html).

The second abstract states, "Post-herpetic neuropathy (PHN) is common in cancer and hematologic malignancy patients. It can be debilitating and difficult to treat effectively. Scrambler therapy, a patient-specific neurocutaneous stimulation device, can be effective in treating chemotherapy induced neuropathy (JPSM 2010) and other neuropathic pain (JPSM 2012)."

These results were from a study of 10 PHN patients. The study reported that the average pain score rapidly diminished from 7.64 at baseline to 0.42 at one month, a 95% reduction, with continued relief at 2 and 3 months. Patients achieved maximum pain relief with less than 5 treatments. (To view the complete abstract, visit http://abstract.asco.org/AbstView_114_96734.html.)

"We are pleased to announce these outstanding early results from these well-respected researchers," said Johnnie D. Johnson, CEO of Competitive Technologies, Inc. "These studies continue to confirm the effectiveness of Scrambler Therapy, as was shown in earlier scientific papers. Research showing our medical device to be beneficial in treating CIPN and PHN is very positive news for patient therapy and for our company."

To facilitate the proper use of Scrambler Therapy ("ST"), there is now available, at no cost to all ST users, an information network and specific software tools (see http://www.scramblertherapy.org/st-net-project.htm).

For more information on Scrambler Therapy™ visit Professor Giuseppe Marineo's official website at http://www.scramblertherapy.org/english.htm. For additional information on the Calmare device, visit www.calmarett.com.

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services. CTTC's staff is focused on the needs of customers and matching those requirements with commercially viable products or technology solutions.

CTTC is the licensed worldwide distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy™" technology developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain (The official "Scrambler Therapy™" technical website is at http://www.scramblertherapy.org/english.htm). The Calmare® device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea.  For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended December 31, 2011, filed with the SEC on April 16, 2012, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Direct inquiries to: Jean Wilczynski, IR Services, LLC (860.434.2465 / info@corpirservices.com).